News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GB Therapeutics Ltd. Obtains US Patent No. 6,677,374 B2 For Nitric Oxide Mimetic Compounds For Neuroprotection In Neurological Or Cognitive Conditions

10/19/2005 5:10:01 PM

MISSISSAUGA, ON, Feb. 17 /PRNewswire/ -- Anthony Giovinazzo, President & CEO of GB Therapeutics Ltd. (GBt), announced today that issuance of U.S. patent No. 6,677,374 had been obtained from the US patent office for the Company's proprietary nitric oxide mimetic compounds as they relate to effecting neurodegeneration, mitigating neurodegeneration and/or effecting cognition enhancement.

"I am very excited about the expansion of our IP estate with this patent which brings the total to 6 issued patents with 9 still pending internationally. The addition of this patent increases the breadth of our Intellectual Property estate, as the patent covers several different families of compounds" said Mr. Giovinazzo.

This patent relates to GBt's work in the field of nitrate esters, and their potential use as treatment for a wide range of diseases characterized by neurodegeneration and loss of mental capacity. GBt was the first to demonstrate that novel nitrates could be engineered to enhance cognitive function, holding promise for the development of new therapeutic agents for the treatment of diseases of the Brain.

About GB Therapeutics Ltd. --------------------------

GBt is supported by venture capital with VenGrowth Capital Partners Inc. as its lead investor. The Company is development based, focusing on building a portfolio of proprietary and in-licensed drug candidates for diseases of the nervous system. The Company's core competency is to identify innovative, cost-effective drugs that provide more effective relief with fewer side effects, and, in the case of neurodegenerative diseases like Alzheimer's Disease, Parkinson's Disease, and ALS, can slow the progression of these diseases. The Company's proprietary chemistry library is made up of molecules that were designed by its founding scientists to be mimetics of Nitric Oxide, with unique targeting attributes. The Company's lead candidate, GT 1061, is a molecule from this library. GT 1061 is targeted for mild to moderate Alzheimer's Disease and is currently in Phase 1a human clinical trials.

GB Therapeutics Ltd.

CONTACT: Anthony Giovinazzo, President & CEO, GB Therapeutics Ltd.,2480 Dunwin Drive, Mississauga, Ontario, L5L 1J9, CANADA, Tel: (905) 607-4903ext 222, Fax: (905) 607-7351, Email:

Read at

comments powered by Disqus